352 related articles for article (PubMed ID: 27223498)
1. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK
Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
Patel BG; Ahmed KA; Johnstone PA; Yu HH; Etame AB
Melanoma Res; 2016 Aug; 26(4):382-6. PubMed ID: 26926151
[TBL] [Abstract][Full Text] [Related]
4. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.
Mastorakos P; Xu Z; Yu J; Hess J; Qian J; Chatrath A; Taylor DG; Kondziolka D; Warnick R; Chiang V; Sheehan J
Neurosurgery; 2019 Apr; 84(4):868-880. PubMed ID: 29846702
[TBL] [Abstract][Full Text] [Related]
8. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
10. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis.
Prabhu RS; Press RH; Patel KR; Boselli DM; Symanowski JT; Lankford SP; McCammon RJ; Moeller BJ; Heinzerling JH; Fasola CE; Asher AL; Sumrall AL; Buchwald ZS; Curran WJ; Shu HG; Crocker I; Burri SH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):459-467. PubMed ID: 28871997
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
[TBL] [Abstract][Full Text] [Related]
12. Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases.
Jhaveri J; Chowdhary M; Zhang X; Press RH; Switchenko JM; Ferris MJ; Morgan TM; Roper J; Dhabaan A; Elder E; Eaton BR; Olson JJ; Curran WJ; Shu HG; Crocker IR; Patel KR
J Neurosurg; 2018 Apr; 130(3):797-803. PubMed ID: 29676690
[TBL] [Abstract][Full Text] [Related]
13. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
14. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
[TBL] [Abstract][Full Text] [Related]
15. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
[TBL] [Abstract][Full Text] [Related]
16. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
Jablonska PA; Muniz T; Ribeiro M; Liu ZA; Ye XY; Devaraja K; Laperriere N; Millar BA; Conrad T; Kongkham P; Butler M; Shultz DB
J Neurooncol; 2023 Aug; 164(1):199-209. PubMed ID: 37552363
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
[TBL] [Abstract][Full Text] [Related]
19. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.
Kim JM; Miller JA; Kotecha R; Xiao R; Juloori A; Ward MC; Ahluwalia MS; Mohammadi AM; Peereboom DM; Murphy ES; Suh JH; Barnett GH; Vogelbaum MA; Angelov L; Stevens GH; Chao ST
J Neurooncol; 2017 Jun; 133(2):357-368. PubMed ID: 28434110
[TBL] [Abstract][Full Text] [Related]
20. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
